Exelixis, Inc.s in-depth stock price analysis indicates that the stock price has rallied 30.19% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 101.46% . Looking at the past 52 week period, the stock price is up at 425.71% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Exelixis, Inc. has a positive value of 272.75 compared to overall market. Exelixis, Inc. (NASDAQ:EXEL) has climbed 8.98% in the past week and advanced 19.29% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 8.1% and the outperformance has advanced to 17.15% for the last 4 weeks period.
Exelixis, Inc. (NASDAQ:EXEL) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.42 points or 1.87% at $22.08 with 6,804,790 shares getting traded. Post opening the session at $22.89, the shares hit an intraday low of $21.95 and an intraday high of $23.02 and the price was in this range throughout the day. The company has a market cap of $6,325 million and the number of outstanding shares has been calculated to be 286,455,920 shares. The 52-week high of Exelixis, Inc. (NASDAQ:EXEL) is $23.02 and the 52-week low is $3.55.
Exelixis Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.09. Analyst had a consensus of $-0.13. The company had revenue of $62.19 million for the quarter, compared to analysts expectations of $45.48 million. The companys revenue was up 531.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.
Company has reported several Insider transactions to the SEC, on Feb 3, 2017, Peter Lamb (EVP, Scientific Strategy & CSO) sold 70,000 shares at 18.65 per share price.On Dec 16, 2016, Carl B Feldbaum (director) sold 25,000 shares at 17.03 per share price.On Dec 9, 2016, Alan M Garber (director) sold 7,832 shares at 16.90 per share price.
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.